{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-087808","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2026-07-29T11:06:13+00:00","discovered_at":"2026-07-29T11:10:00.711334+00:00","generated_at":"2026-07-29T11:10:14.693338+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"uniQure reports Q2 net loss $81.1M; AMT-130 BLA submission on track for Q3 2026","bullets":["Net loss $81.1M ($1.22/share) vs $37.7M ($0.69) in Q2 2025; revenue $5.8M (+$0.5M).","Cash $810.3M after $259M June offering; runway into 2030.","AMT-130 BLA submission for Huntington's on track for Q3 2026; four-year data expected Sept 2026.","AMT-260 Phase I/IIa: 3 of 6 patients had 79-100% seizure reduction; no SAEs related to drug.","AMT-191 Fabry data: dose-dependent α-Gal A activity up to 229.6x normal; all 11 patients off ERT."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-087808","json":"https://secwatch.observer/filing/0001104659-26-087808.json","markdown":"https://secwatch.observer/filing/0001104659-26-087808.md","text":"https://secwatch.observer/filing/0001104659-26-087808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/0001104659-26-087808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/qure-20260729x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T11:10:14.693338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}